title: Efficacy of intravitreal bevacizumab to treat retinal angiomatous proliferation stage II and III.
abstract: OBJECTIVE
  To evaluate the efficacy of intravitreal bevacizumab to treat retinal angiomatous proliferation (RAP) stages II and III.
  
  
  METHODS
  A retrospective, interventional, nonrandomized multicentric study was performed. The files, optical coherence tomography (OCT) scans, indocyanine green, and fluorescein angiograms of patients with RAP stages II and III who had been treated by intravitreal bevacizumab were retrospectively examined. Final visual acuity, number of injections, and appearance of adverse events were considered as main outcome indicators.
  
  
  RESULTS
  Twenty-six eyes from 24 patients (9 male and 15 female) were treated by intravitreal bevacizumab. Fourteen eyes presented RAP stage II and 12 eyes presented RAP stage III. Mean age was 76+/-9 and 79+/-6 years, respectively. Mean initial best-corrected visual acuity (BCVA) was logMAR 0.60+/-0.24 and 1.13+/-0.37, respectively. Mean BCVA was 0.62+/-0.26 and 1.06+/-0.37, respectively, at 6 months (p=0.96 and 0.10, respectively, Student t test for paired data) and 0.63+/-0.26 and 1.04+/-0.37, respectively, at 12 months (p=0.82 and p=0.06, respectively, Student t test for paired data). The average number of injections during the first year was 3.4 and 3.2, respectively.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab may stabilize visual acuity during the first year in RAP lesion stage II and III. Visual prognosis seems to be better in RAP II lesions.
authors.affiliation: Pío del Río Hortega University Hospital, Valladolid and Alicante Institute of Ophthalmology, Alicante, Spain. javmonmor@hotmail.com
authors.forename: Javier A
authors.initials: JA
authors.lastname: Montero
authors.forename: Maria I
authors.initials: MI
authors.lastname: Fernandez
authors.forename: Francisco
authors.initials: F
authors.lastname: Gomez-Ulla
authors.forename: José M
authors.initials: JM
authors.lastname: Ruiz-Moreno
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000798:Angiomatosis / Q000145:classification / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004396:Coloring Agents; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007208:Indocyanine Green; D007267:Injections; D008297:Male; D012164:Retinal Diseases / Q000145:classification / Q000188:drug therapy*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004396:Coloring Agents; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D007208:Indocyanine Green